European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C
Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.
The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.
You may be interested
EU Poll: Greeks overwhelmingly convinced of widespread corruptionmakis - Dec 12, 2017
Corruption in Greece is an ongoing political issue, that has been debated to death over the past 35 years. Now…
Turkish PM Yildirim escalates rhetoric against Greecemakis - Dec 12, 2017
Two days before his arrival in Greece, Turkish PM Binali Yildirim directly disputed the current Status Quo in the Aegean…
One in three Greeks unable to afford basic material goodsmakis - Dec 12, 2017
One in three Greeks or 32% in 2016 were unable to enjoy basic material goods and social benefits, according to…